ArticleJTO clinical and research reports2024

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.

Tejas Patil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.